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Background: Recent clinical studies suggest that inflammatory mediators have huge potential in individualized
therapy and in efficacy screening and can be utilized as biomarkers for a plethora of pathological conditions. The
standard approach for detecting and measuring these inflammatory mediators is via blood samples. Nevertheless,
there is no scientific report providing solid evidence on the most suitable blood compartment that will give the
optimal inflammatory mediator measurement, or regarding the diurnal variation of circulating mediators. In this
study, we present the biological variability of circulating cytokines and chemokines from healthy individuals (mean
age 59 years) assessed by a novel membrane-based assay.
Methods: Fifteen males and an equal number of females (all above 50 years) with no known inflammatory
condition were selected. Through a planar method, named Proteome Profiler™, improved with fluorescence
readout into a semi-quantitative multiplex assay, a screening of 36 inflammatory mediators was performed in serum
and plasma of morning and afternoon blood withdrawals.
Results: The multiplex analysis revealed that the physiological variability of several circulating inflammatory
mediators was relatively small within a cohort of 30 healthy aging subjects. There was no substantial gender effect
in the inflammatory mediator profile. On the contrary, most of the cytokine/chemokine values measured in the
afternoon collection were found to be higher compared to the morning ones, particularly in plasma.
Conclusions: In this study we provide evidence that circulating cytokine and chemokine levels of healthy
individuals are elevated when blood is sampled in the afternoon compared to the morning, as influenced by the
circulating cortisol levels. Furthermore, we report significant differences between cytokine/chemokine levels
measured in serum and plasma. Our results provide essential information for future studies that will focus on
examining circulating inflammatory mediator differences between healthy and diseased individuals.
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The term “cytokine” was first introduced in the 70s [1].
The word “cytokines” entails hormone-like molecules se-
creted in response to inducing stimuli, which can origin-
ate from white blood cells or other sources (fibroblasts,
endothelial cells, epithelial cells, etc.). In the last two de-
cades the connotation of the word “cytokine” adopted
various meanings, depending on the biological context
where it has been identified. Starting from a mere role
of effector in the cell-mediated immune response, cyto-
kines have been shown to be involved in aging-related
diseases where they orchestrate the physio-pathological
development of several diseases [2,3]. Evidence from
both experimental and clinical trials indicates that in-
flammatory mediators are of paramount importance in
the pathogenesis of chronic heart failure (HF), contribut-
ing to cardiac remodelling and peripheral vascular dis-
turbances [4]. Although the role of the cytokines during
the progression to HF is still unclear, several lines of evi-
dence suggest that inflammatory mediators play benefi-
cial as well as detrimental roles in the development of
the pathology [5] and can predict the development and
the outcome of HF.
Chronobiology is a well-known entity [6] that plays a
crucial role in many physiological and patho-physiological
situations [7]. However, evidence about the diurnal vari-
ability of cytokines is scarce. Studies have focused on a
limited panel of cytokines [8] leaving unexplored many
others. However, profiling in time could add to clinical
definition and management [9]. Furthermore, while sam-
pling blood is a routine way for detecting and measuring
inflammatory mediators, the selection of medium (blood
compartment) can play a crucial role in the measured re-
sult (and is often imposed/dictated by the methodology
and protocol offered by various assay manufacturers). Up
to this point, no solid documentation exists on the
medium that offers the most accurate results. In this
study, we assessed the physiological differences of 36 cir-
culating cytokines/chemokines in healthy aging male and
female individuals, uncovering the inflammatory baseline
for the aging inflammatory-related diseases. Furthermore,
we evaluated the variability between morning/afternoon




Thirty healthy volunteers (15 males and 15 females) above
50 years of age were recruited under the supervision of a
physician or cardiologist who overall judged whether each
individual fulfilled the general criteria for a healthy person.
The subjects were pre-screened and excluded in the case
of an on-going chronic inflammatory disease, respiratory
problems (asthma or COPD), hypertension, previoushistory of MI, recent illness of any kind in the last three
months and/or use of anti-inflammatory drugs. Mean age ±
SD of the volunteers was 59.4 ± 6.0 years (ranging between
50 and 71 years), and there was no gender-specific differ-
ence (average age for males 58.8 ± 6.0, ranging between 52
to 71 years and average age for females 60.1 ± 6.4, ranging
between 50 and 70 years).
Volunteers were scheduled for the first blood with-
drawal in the morning between 9-10 am and in the
afternoon of the same day between 2-3 pm.
The recruitment was performed according to the Dutch
Medical Ethical Committee (protocol: METC 11-3-056)
and in accordance with the Declaration of Helsinki. All
study participants signed the informed consent.
Sample collection
Venous blood samples were collected from the cephalic
vein (or antecubital vein) of the healthy volunteers. Serum
and plasma were collected in special pre-vacuumed con-
tainers (Vacuette® K3 EDTA and Vacuette® plus clot acti-
vator, Greiner Bio-One, Austria). Blood was stored at 4°C
for 3 h. Samples were then centrifuged at 2000 g for
10 minutes at 4°C and then immediately aliquoted and
stored at -80°C until further analysis.
Multiplex membrane-based immunoassay
Human Cytokine Array Panel A (R&D Systems™) was
used according to the manufacturer instructions (see the
Extracellular Factors session on www.rndsystems.com/
product_detail_objectname_ProteomeProfilerArray.aspx)
to determine the semi-quantitative presence of 36 cyto-
kines. A total volume of 1000 μl (maximum possible vol-
ume) was poured per membrane for each individual and
each condition that we were interested to determine
(serum/plasma, AM/PM).
The aforementioned original Proteome Profiler proto-
col was adapted after step #9 in order to acquire semi-
quantitative measurements by the use of a fluorescence
read-out [10]. The analytes measured are expressed in
Median Fluorescence Intensity (MFI) units.
Statistical analysis
Raw data were imported in R. LIMMA package in R, a
software environment for statistical computing; heat
maps (http://www.r-project.org/) were used for hierarch-
ical cluster analysis of the cytokines/chemokines in hu-
man blood. Graph pad statistical program (GraphPad
Software, San Diego, USA) was used for graphics and
statistical comparisons of data. Two-way ANOVA of re-
peated measures with a Bonferroni post hoc test was
performed, in order to compare the difference between
AM and PM measurements. Patients with missing values
were excluded from the analysis. Values with p <0.05
were considered statistically significant.
Figure 1 (See legend on next page.)
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Figure 1 Two-dimensional cluster analysis of blood samples. (a) The similarity between individual profiles in different conditions clustered
according to the dendrogram on the top, whereas, the relationship between inflammatory molecules by the dendrogram on the left. Sample
times, genders, sample types distribution has been color coded and placed below the relative individual profiles cluster analysis (dendrogram on
the top). The color codes are: yellow/morning, orange/afternoon (b); blue/male, pink/female (c); brown/serum, red/plasma (d). The color-coded
florescence intensity of all the values measured in the study are illustrated by the heatmap. White spots are missing values.
Figure 2 Relative expression of the four cytokines with the highest
circulating levels. Four cytokines out of 36 assessed, were shown to
have MFI above the threshold in every condition measured. Plasma
PM has generally higher values compared to the ones measured in
the other conditions (p < 0.001). ***p < 0.001 and corresponds to
comparison to plasma AM. MFI, Median Fluorescence Intensity.
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In total, 36 inflammatory molecules were measured in
blood samples of 30 healthy aging subjects. The com-
plete sample set, i.e. plasma, serum, morning, afternoon
withdrawal, was obtained from 22 subjects. Samples not
included in the analysis did not differ from those in-
cluded (data not shown).
The use of fluorescence in the membrane assay ap-
proach [10] allowed us to observe which cytokines and
chemokines were undetectable, absent or present in very
low levels in serum or plasma. To better understand the
complexity behind the inflammatory profiles in the dif-
ferent conditions a two-dimensional cluster analysis was
performed (Figure 1a). Combining the sample clustering
and the detected intensities of the inflammatory media-
tors, we generated three heat maps with the following
conditions: gender difference, sample type and sampling
time (Figure 1b, c, and d respectively). Although the
aforementioned variables had a mixed and heteroge-
neous distribution, the differences in the pattern be-
tween female and male, morning and afternoon, serum
and plasma, when graphically represented by the heat
map were not observed: the clustering was based on the
profile of the individuals, hence the output remained the
same as in Figure 1a.
In order to determine which of the assessed analytes
were the most abundant in the samples we chose a strict
threshold. The reason for the use of the threshold was
to make sure that the values obtained were sufficiently
higher compared to the background. This cut-off point
was set as twice the average of the values of the negative
controls (MFI = 0.99). In Figure 2, four analytes - out of
the 36 analyzed – are presented that were detectable
with high intensities in all the conditions measured;
these cytokines were RANTES (CCL5), Sicam-1, Serpin
E1, MIF (see Table 1 for more details).
From the remaining 28 inflammatory mediators mea-
sured, 10 were found to have a fluorescent intensity
above the threshold in at least two of the four conditions
tested (Figure 3). Interestingly, with the exception of Ser-
pin E1, we consistently observed higher levels in the
plasma sample taken in the afternoon, compared to
serum and morning plasma values (Table 1).
Discussion
To our knowledge, this is the first study in which an ex-
tensive range of physiological cytokine and chemokineprofiles is compared between healthy males and females.
Furthermore, this study provides evidence for the essen-
tial variability that might occur when blood is sampled
as plasma or serum and at two distant time points along
the circadian rhythm (AM/PM).
Age-related changes in circulating inflammatory pro-
files might be the key point to focus on when imple-
menting the diagnostics and prognostics of various
diseases, i.e. cancer [11], HF [12] etc. Most importantly,
there is scientific evidence that answer to drugs adminis-
tration can be stereotyped, based on time of administra-
tion [13]. In the last two decades, there has been an
abundance of reports on the involvement of the inflam-
matory response to the onset of HF [14], however a top
selection of the inflammatory biomarkers has not yet
been accomplished. With reference to seminal studies
which report a variation between the HF incidences in
men and women (women with HF are better protected
against apoptotic death signals and show a later onset of
cardiac decompensation compared to men) [15], we
studied the physiological thresholds in both genders.
Furthermore, this investigation was conducted within an
aged population where the risks of HF development are
known to be higher [16,17], and the circulating inflamma-
tory mediators are expected to be elevated [18]. To
achieve this, we generated hierarchy of clusters from the
intensities detected in every individual for each condition
Table 1 Serum and plasma levels of cytokines and chemokines for each condition measured
Serum AM (n = 22) Serum PM (n = 22) Plasma AM (n = 22) Plasma PM (n = 22)
High MFI RANTES 7.9 ± 1.4 7.8 ± 1.1 8.5 ± 1.1 10.3 ± 1.2
Sicam-1 6.8 ± 1.1 6.7 ± 0.8 7.6 ± 1.1 9.0 ± 1.0
Serpin E1 6.0 ± 1.0 6.6 ± 0.9 6.1 ± 0.9 6.5 ± 0.6
MIF†† 3.4 ± 0.5 3.5 ± 0.4 4.0 ± 0.5 5.1 ± 0.5***
Medium MFI IL-16††† 1.2 ± 0.2 1.2 ± 0.1 1.2 ± 0.1 1.7 ± 0.1***
IL-1ra††† 1.2 ± 0.2 1.3 ± 0.1 1.2 ± 0.1 1.7 ± 0.1***
C5a††† 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.6 ± 0.1***
GROa††† 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.5 ± 0.1***
GM-CSF††† 0.9 ± 0.0 1.0 ± 0.1 1.0 ± 0.0 1.5 ± 0.1***
SDF-1††† 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.0 1.5 ± 0.1***
CD40 Ligand††† 1.0 ± 0.1 1.1 ± 0.1 0.9 ± 0.0 1.3 ± 0.1***
Low MFI Strem-1†† 0.9 ± 0.0 1.0 ± 0.1 1.0 ± 0.0 1.5 ± 0.1***
IP-10††† 0.8 ± 0.0 0.9 ± 0.1 0.9 ± 0.0 1.4 ± 0.1***
TNF-a†† 0.9 ± 0.0 0.9 ± 0.1 0.9 ± 0.0 1.4 ± 0.1***
IL-2††† 0.8 ± 0.0 0.9 ± 0.1 0.9 ± 0.0 1.4 ± 0.1***
IL-8††† 0.8 ± 0.0 0.8 ± 0.0 0.9 ± 0.0 1.3 ± 0.1***
MIP-1ß†† 0.8 ± 0.0 0.8 ± 0.0 1.0 ± 0.1 1.3 ± 0.0***
IL-1ß††† 0.8 ± 0.0 0.8 ± 0.0 0.9 ± 0.0 1.3 ± 0.0***
G-CSF††† 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.4 ± 0.1***
I-309 /CCL1††† 0.9 ± 0.2 0.9 ± 0.1 0.9 ± 0.1 1.4 ± 0.1***
INF-g††† 0.7 ± 0.0 0.7 ± 0.0 0.8 ± 0.0 1.2 ± 0.0***
IL-1a††† 0.7 ± 0.0 0.7 ± 0.0 0.8 ± 0.0 1.2 ± 0.0***
IL-4††† 0.7 ± 0.0 0.8 ± 0.0# 0.8 ± 0.0 1.2 ± 0.0***
IL-5††† 0.7 ± 0.0 0.7 ± 0.0 0.8 ± 0.0 1.2 ± 0.0***
IL-6††† 0.8 ± 0.0 0.8 ± 0.0 0.9 ± 0.0 1.3 ± 0.0***
IL-10††† 0.7 ± 0.0 0.7 ± 0.0 0.8 ± 0.0 1.1 ± 0.0***
IL-12 p70††† 0.8 ± 0.0 0.8 ± 0.0 0.9 ± 0.0 1.3 ± 0.1***
IL-13††† 1.0 ± 0.2 0.9 ± 0.1 0.9 ± 0.1 1.3 ± 0.1***
IL-17††† 0.8 ± 0.0 0.8 ± 0.0 0.9 ± 0.0 1.3 ± 0.0***
IL-17E††† 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.4 ± 0.1***
IL-23††† 0.7 ± 0.0 0.8 ± 0.0## 0.8 ± 0.0 1.2 ± 0.0***
IL-27††† 0.7 ± 0.0 0.7 ± 0.0# 0.8 ± 0.0 1.1 ± 0.0***
IL-32a††† 0.7 ± 0.0 0.7 ± 0.0 0.8 ± 0.0 1.1 ± 0.0***
I-TAC††† 0.7 ± 0.0 0.8 ± 0.0# 0.8 ± 0.0 1.2 ± 0.0***
MCP-1††† 0.7 ± 0.0 0.8 ± 0.0# 0.8 ± 0.0 1.2 ± 0.0***
MIP-1a††† 0.7 ± 0.0 0.7 ± 0.0# 0.8 ± 0.0 1.2 ± 0.0***
NOTE. #significant at p < 0.05, ##or ††significant at p < 0.01, *** or †††significant at p < 0.001.
MFI = Median Fluorescence Intensity.
The table is divided in three parts: the “high” intensities (on top) represent the cytokines that are more abundant in the circulation. The “medium” intensities (in
the middle) represent the cytokines with MFI values above the threshold for at least two conditions. The “low” intensities (on the bottom) represent all the
cytokines with MFI values below the threshold. Values are expressed in MFI ± SEM. Differences compared to “Serum AM” are marked with #and the ones
compared to “Plasma AM” with *. The statistical analysis with two-way ANOVA further demonstrated that there is a “significant interaction” between serum and
plasma. Therefore, the increase between AM and PM values is dependent on the type of matrix (serum or plasma) that is used. This interaction is indicated by †for
each corresponding cytokine/chemokine that is found to show a “significant interaction”.
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sampling). All observations started in one cluster
(Figure 1a), and splits were indiscriminately generated asone moves down the hierarchy. The colored stripes origin-
ating from the cluster analysis clearly indicated that the
physiological inflammatory profile is evenly distributed for
Figure 3 Relative expression levels of the analytes with circulating levels above threshold in (at least) two of the four conditions tested. The
graph represents the selection of the analytes that showed low signals but were still above the threshold for at least two conditions. Note that all
plasma PM values are significantly (p < 0.001) increased compared to Plasma AM. MFI, Median Fluorescence Intensity.
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type). In other words, the clustering of both genders seen
in our study (Figure 1b) is showing that no significant dif-
ference based on gender is present. These results suggest
that the onset of an inflammatory-associated disease is
not triggered by a difference in the normal physiological
levels of the circulating cytokine profiles. This hypothesis
should be further confirmed in a larger retrospective
study with the inclusion of individuals that progress into
HF development.
The choice for the sampling between serum or plasma
is often driven by the requirements of the immunoassays
that the investigator is planning to utilize and this is
usually imposed by the specific assay manufacturer/sup-
plier used. Choosing serum rather than plasma always
raises the questions whether in the “other” sample the
levels of the same analyte of interest would be different
(and vice versa). In some studies it was demonstrated
that a limited number of circulating cytokines have a dif-
ferent concentration outcome when measured in either
serum or plasma [19]. Various scientific groups have
demonstrated serum-plasma variability owing to a var-
iety of factors, such as the release of cytokines from
platelets during clotting or centrifugation [20,21], the
type of blood collection tubes [22], degradation during
the clotting process [21], as well as the “matrix effects”
of multiplex systems and sample preparation artifacts
(leading to non-systematic differences) [23]. We cannot
exclude that one of these factors could have influenced
the small differences observed. However, to pinpoint
which of those factors is the real responsible, a differentstudy focusing on the methodological aspects would be
more appropriate.
Incidentally, when comparing serum vs. plasma in our
measurements by membrane-based assay, a strong trend
of high given values in “plasma PM” was observed. In-
deed, for almost all the inflammatory mediators mea-
sured, the plasma PM values were significantly higher
than in the other conditions (serum PM or serum AM).
However, no profound interpretation of morning/after-
noon changes could be given. This is indeed a limitation
of the study, since we did not measure other potential
factors that might have been responsible for the small
variation observed. Unfortunately, this area in literature
is still grey and no conclusive explanation has been given
regarding the differences observed between measure-
ments of inflammatory mediators in plasma or serum
[21]. In addition, Wong et al. have shown that plasma
cytokine values are consistently higher compared to the
ones measured in serum [21]. Lastly, the de Jager group
has reported important differences in the cytokine levels
depending on the sample type. Serum samples show
higher levels of cytokines at 4°C compared to plasma sam-
ples and this seems to be due to the fact that serum sam-
ples have generally higher levels of chemokines [22,24].
Furthermore, a large piece of evidence suggests that
the diurnal rhythm has a pronounced effect on a variety
of physiological or pathophysiological situations [7] -
including the cardiovascular system [9]. In addition, re-
cent studies such as the one from Benito et al. on teat
cytokine/chemokine levels, have been pointing towards a
time-dependent relationship as regards to the levels of
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CLXL10/IP-10, VEGF etc [25]. However, to the best of
our knowledge, no systematic effort has been conducted
so far to systematically investigate the diurnal variation
of chemokines and cytokines, and their potential impact
on classification at screenings/general-practices. We hy-
pothesized that measuring cytokine/chemokine levels in
different time points of the diurnal rhythm would dem-
onstrate variable inflammatory mediator levels. Indeed,
we showed that the levels of almost all the analytes mea-
sured - with the exception of Serpin E1 and RANTES -
were elevated in plasma PM samples when compared to
the other conditions assessed. The increased levels of
several inflammatory mediators during the PM blood
collection point can be attributed to the effect of low
cortisol-circulating levels. It is well-documented that hu-
man cortisol levels peak in the morning (approximately
8.30 am) and reach a minimum around 22.30 pm [26]
and it has been shown that cortisol has a suppressive ef-
fect on IFN-gamma, TNF-alpha, IL-1alpha, IL-12 [8], IL-
6, as well as inhibitory effects on Th1 and Th2 immune
response [27]. On these grounds, high levels of circulat-
ing cortisol (peaking at AM sampling), lead to depressed
levels of the cytokines under investigation. This hypoth-
esis is in agreement with well-established knowledge
from previous years, showing that glucocorticoids (and
cortisol specifically) are potent inhibitors of the pro-
inflammatory and inducers of the anti-inflammatory
hormones in the body [28,29].
Conclusions
Plasma collected in the afternoon contains higher con-
centrations of cytokines and chemokines than serum
and plasma collected in the morning and serum sampled
in the afternoon. Overall, the aim of this study was to
expedite the transition of the circulating inflammatory
markers, in order to investigate their potential imple-
mentation in the clinical setting as biomarkers. Collect-
ively, the present data provide important information
regarding the diurnal rhythm of cytokine/chemokine
profile in serum and plasma in healthy aged individuals.
In conclusion, this study demonstrates the importance
of diurnal rhythm in the regulation of a wide range of
cytokines/chemokines and provides evidence for the first
time for the variability of their levels depending on the
medium (plasma or serum). Hence, great consideration
should be given on the blood sampling time, as well as
the use of serum or plasma, in order to avoid inconsist-
encies in the measuring of inflammatory mediators for
prediction of HF or any other pathological condition.
Furthermore, this proves the great need of a globally
standardized method/protocol in measuring inflammatory
cytokines/chemokines, in order to allow for the repro-
ducibility and comparability between different researchgroups/laboratories. Introducing a unified method in
sampling/measuring and defining the underlying reasons
for the variabilities and their mechanisms could prove of
crucial importance in the hunt for novel biomarkers in
HF, cancer and any other pathophysiology characterized
by an inflammatory response.
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